🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are on the rise worldwide, with data suggesting over 82 million new cases annually. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, alternatively called Nuzolvence, was authorized by the US FDA in December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This authorization signifies a huge turning point in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on findings published in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which uses an injection and a pill. The trial included nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. Access to a single-dose, oral treatment like this is seen as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.